Previous studies have reported the clinical utility of bone turnover markers associated with bone metastasis [10,11], whereas the present study is the first to report that both P1NP and TRACP-5b, regardless of the presence of metastasis, are high in patients at risk of progression to CRPC. The gene discussed is ACP5; the disease is bone metastasis.